Transmembrane glycoprotein gp41 · SINGLE PROTEIN · Human immunodeficiency virus
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Transmembrane glycoprotein gp41 shows approved-linked disease relevance led by HIV infection. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O40239. Start with HIV infection, then reuse UniProt O40239 as the stable protein anchor across project notes and exports.
Start with HIV infection, then reuse UniProt O40239 as the stable protein anchor across project notes and exports.
Transmembrane glycoprotein gp41 shows approved-linked disease relevance led by HIV infection. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with HIV infection because it currently carries approved-linked support. Linked drugs include ENFUVIRTIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyEnv polyprotein
Review this target as Transmembrane glycoprotein gp41, mapped to UniProt O40239. ChEMBL maps the protein component as Env polyprotein. Sequence length is 109 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Transmembrane glycoprotein gp41 as ChEMBL target CHEMBL2362987, mapped to UniProt O40239. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Transmembrane glycoprotein gp41 is the right protein anchor across sources, using UniProt O40239 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why HIV infection is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Transmembrane glycoprotein gp41 |
| Target Type | SINGLE PROTEIN |
| Organism | Human immunodeficiency virus |
| UniProt | O40239 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Env polyprotein |
| UniProt Accession | O40239 |
| Component Type | Protein |
| Sequence Length | 109 aa |
Env polyprotein
Review this target as Transmembrane glycoprotein gp41, mapped to UniProt O40239. ChEMBL maps the protein component as Env polyprotein. Sequence length is 109 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Transmembrane glycoprotein gp41 shows approved-linked disease relevance led by HIV infection. 3 more disease programs remain visible in the same review block.
Start review with HIV infection because it currently carries approved-linked support. Linked drugs include ENFUVIRTIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.